Xiaoyang Qi, a research scientist in the Division of Human Genetics at Cincinnati Children's Hospital Medical Center, has discovered the compound SapC-DOPS, that has potential for brain cancer tr
An experimental cancer treatment developed locally has the potential to revolutionize the way doctors treat the disease.
The compound, called SapC-DOPS, tricks cancer cells into committing suicide without harming healthy tissues - and with no apparent side effects - developers say.
Bexion Pharmaceuticals in Covington, which manufactures the compound, plans to begin the first phase of testing it on humans by mid-2011, said president and CEO Ray Takigiku."There's nothing like this kind of drug in anyone's pipeline," he said ...
The compound, called SapC-DOPS, tricks cancer cells into committing suicide without harming healthy tissues - and with no apparent side effects - developers say.
Bexion Pharmaceuticals in Covington, which manufactures the compound, plans to begin the first phase of testing it on humans by mid-2011, said president and CEO Ray Takigiku."There's nothing like this kind of drug in anyone's pipeline," he said ...
No comments:
Post a Comment